Navigation Links
Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington
Date:11/9/2007

KIRKLAND, Wash., Nov. 9 /PRNewswire-FirstCall/ -- CellCyte Genetics Corporation (OTC Bulletin Board: CCYG) announced today that is has received notice of the issuance of a U.S. patent (U.S. Patent No. 7,282,222) for its unique methods and compositions approach to deliver and direct stem cells to target organs in the body.

Using this now-patented technology, exclusively licensed to CellCyte from the US Department of Veterans Affairs, the company is developing stem cell enabling therapeutic products designed to allow more efficient delivery and significantly increased retention of adult stem cells to diseased and other target organs, such as the heart.

Dr. Ronald Berninger, Chief Scientific Officer of CellCyte Genetics explains, "The goal of CellCyte's stem cell targeting/retention therapies is to enhance the number of cells available for regeneration of damaged tissue, and thereby markedly increase opportunities for healing and restoring organ function. The company's first product in development, CCG-TH30, is designed to target autologous bone-marrow-derived (adult) stem cells to the heart of patients after a heart attack."

"In preclinical models, CCG-TH30 has been shown to increase the retention of stem cells up to as much as 77% in pre-clinical models as compared to conventional methods, which achieve only up to about 6%," Berninger states. "Importantly, CellCyte's product candidate, along with stem cells, can both be delivered intravenously through a patient's circulatory system without an invasive procedure."

Company CEO, President and Chairman, Gary A. Reys emphasizes the importance of the patent's issuance to the company's position. Reys states, "This patented technology is significant, as it has the potential to fill an important missing piece in the field of regenerative medicine, namely, the ability to target and then keep cells in an organ of interest, in this case, the heart. The issuance of a patent for this platform assures
'/>"/>

SOURCE CellCyte Genetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. Pressure BioSciences, Inc. Issued First Patent in Canada
4. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
5. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
6. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
7. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
8. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
9. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
10. Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
11. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... In preparation for VARTECH 2014, 2FA, Inc., ... focused on authentication and SSO announced today that their ... generate a OTP through the presentation of an RFID ... RFID authentication, 2FA,s solutions have leveraged the existence of ... RFID authentication is broadly deployed in healthcare and other ...
(Date:9/15/2014)... Sept. 15, 2014   Global Science & ... scientific products and services for satellite and weather ... for Integrated Services (OASIS) from the General Services ... selected to provide the government best-value solutions for ... (SB) category in Pool 4. The OASIS SB ...
(Date:9/15/2014)... a patient has sepsis, a life-threatening condition in which ... often too fast for antibiotics to help. A new ... a team at Harvard,s Wyss Institute for Biologically Inspired ... , "Even with the best current treatments, sepsis ... 30 percent of the time," said Mike Super, Ph.D., ...
(Date:9/15/2014)...  iVinci Health LLC, the company behind the healthcare ... branded as VisitPay®, has successfully closed $5 million in ... a new extension to VisitPay® – an online Payment ... way for patients to manage their medical bills and ... their families. The new round of funding, ...
Breaking Biology Technology:2FA, Inc. Announces RFID-based One-Time Password (OTP) Authentication 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 3Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 2iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 3
... FRANCISCO, Calif., Nov. 1, 2010 diaDexus, Inc. (OTC ... focused on the development and commercialization of patent-protected ... cardiovascular disease, today announced that the company, formerly known ... Board under the ticker symbol (VXGN), has been renamed ...
... Nov. 1, 2010 Amgen (Nasdaq: AMGN ) ... Ph.D., will urge members of a U.S. Food and Drug ... to establish approval standards that ensure patient safety and follow ... policy will follow," Dr. Miletich said.  "Amgen believes biosimilars have ...
... ... ... var shortURL = ""; BitlyCB.alertResponse = function(data) ... first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var key in first_result) { ...
Cached Biology Technology:diaDexus Announces Name Change From VaxGen 2diaDexus Announces Name Change From VaxGen 3Amgen to Provide Testimony at FDA Hearing on Biosimilars 2Amgen to Provide Testimony at FDA Hearing on Biosimilars 3Amgen to Provide Testimony at FDA Hearing on Biosimilars 4NEURO-BIOTECH CORPORATION: Updates and latest developments 2NEURO-BIOTECH CORPORATION: Updates and latest developments 3NEURO-BIOTECH CORPORATION: Updates and latest developments 4NEURO-BIOTECH CORPORATION: Updates and latest developments 5NEURO-BIOTECH CORPORATION: Updates and latest developments 6NEURO-BIOTECH CORPORATION: Updates and latest developments 7NEURO-BIOTECH CORPORATION: Updates and latest developments 8NEURO-BIOTECH CORPORATION: Updates and latest developments 9
(Date:9/15/2014)... Mass. (September 15, 2014) The so-called central ... makes proteinhas long provided a simplified explanation for ... living organisms. , In reality, of course, ... schema first articulated nearly 60 years ago by ... double-helix structure. For one, there are multiple types ...
(Date:9/15/2014)... both plants and animals alike. , Understanding just how ... to the design of better drugs for diabetes patients ... vegetables farmers are able to grow. Stanford University researchers ... cell by piecing together proteins slightly wider than the ... determine the size, shape and orientation of one of ...
(Date:9/15/2014)... will allow us to better understand how the ... scenarios and provide the type of environmental data ... and siting of protected areas," said Paula Whitfield, ... Coastal Ocean Science (NCCOS) and lead author of ... within the temperate-tropical transition zone, where historically, both ...
Breaking Biology News(10 mins):Scientists discover RNA modifications in some unexpected places 2X-rays unlock a protein's SWEET side 2X-rays unlock a protein's SWEET side 3Study finds warming Atlantic temperatures could increase range of invasive species 2
... D.C., November 21, 2010 -- For centuries, hunters have imitated ... carving wooden bird calls. Now a team of physicists at ... characteristics of real bird song with a simple physical model ... know if you [could] build a simple device, which has ...
... baby,s first blurted "bowl!," for the word "ball" to the ... vocalizations is one of humankind,s most remarkable attributes -- and ... Not so for people who are afflicted with ... stigma of affected speech. Nor so for engineering professor Michael ...
... , Researchers in the United States have developed a ... from a patient,s own bone marrow. The research, published ... suffering from abnormally developed bladders, but also represents another ... research, led by Dr Arun Sharma and Earl Cheng ...
Cached Biology News:Simple rubber device mimics complex bird songs 2Air flows in mechanical device reveal secrets of speech pathology 2New study into bladder regeneration heralds organ replacement treatment 2
Request Info...
...
... High Resolution - Efficiently ... 50 to 1000 bp. ... sizing PCR fragments, small ... restriction enzyme digestion, and ...
... ZMD.358. Immunogen: Synthetic peptide ... of human mouse and rat ... human and mouse LRP5 proteins. ... controls: mouse LRP5-pSEC-tag-transfected 293T cells ...
Biology Products: